Skip to main content
Smart Investors Daily
Pfizer Inc. logo

NYSE · PFE

Pfizer Inc.

Healthcare · Drug Manufacturers - General

$28.06

Down-$0.52 (-1.85%)

Updated Nov 20, 2026, 1:49 AM

SID Score

7.0/10

Composite research score

Smart Money

54/100

Neutral

Market cap
146.75B
P/E ratio
14.94
Dividend yield
6.13%
52-week range
$23.62 – $31.44
Volume
37.66M
Avg. volume
68.83M

Price performance · PFE

PFE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

PFE closed at $27.54 after 21 trading sessions, down 9.47% for the selected period.

Last close
$27.54
Period change
-9.47%
Period low
$27.54
Period high
$30.79
Daily close
View OHLC price history
PFE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$27.92$27.99$27.44$27.5435.53M
Nov 18, 2026$28.06$28.5362$28.00$28.0637.66M
Nov 17, 2026$28.48$28.665$28.35$28.4735.36M
Nov 16, 2026$29.23$29.28$28.81$28.8640.15M
Nov 13, 2026$28.92$28.99$28.62$28.8921.6M
Nov 12, 2026$29.746$29.77$28.825$28.8330.78M
Nov 11, 2026$29.06$29.495$28.95$29.4526.03M
Nov 10, 2026$29.15$29.38$28.95$29.3631.13M
Nov 9, 2026$29.59$29.63$28.98$29.2345.77M
Nov 6, 2026$29.07$29.43$28.54$29.3948.32M
Nov 5, 2026$31.09$31.44$29.85$29.8853.05M
Nov 4, 2026$30.75$30.90$30.04$30.7949.92M
Nov 3, 2026$30.68$31.06$29.89$30.0053.06M
Nov 2, 2026$30.45$31.04$30.20$30.6750.82M
Oct 30, 2026$30.51$30.67$30.14$30.5245.49M
Oct 29, 2026$29.99$30.18$29.61$29.9534.26M
Oct 28, 2026$29.49$29.815$29.22$29.4527.26M
Oct 27, 2026$29.54$29.86$29.51$29.8025.59M
Oct 26, 2026$30.00$30.305$29.715$29.7925.66M
Oct 23, 2026$30.28$30.32$29.81$30.0329.48M
Oct 22, 2026$30.045$30.44$29.88$30.4228.7M

Latest PFE news

The latest Smart Investors Daily articles mentioning PFE.

PFE research

Overview

Company profile and research snapshot.

Company profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$30.00
Implied upside
—
Analysts
15
PFE recent ratings
DateFirmRatingTarget
Nov 6, 2026Freedom BrokerBuy—
Nov 5, 2026GuggenheimBuy—
Nov 4, 2026CitigroupNeutral—
Nov 4, 2026ScotiabankSector Outperform—
Nov 4, 2026UBSNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 14, 2026

Pfizer (PFE) Secures $1.5 Billion For Berobenatide Development

Pfizer (NYSE:PFE) announced a partnership with Blackstone Life Sciences to co-fund late stage development of berobenatide, its GLP-1 obesity drug candidate. The arrangement provides up to $1.5b in development funding for berobenatide, focused on chronic weight management and obesity related conditions. Pfizer keeps full operational control of berobenatide, while Blackstone Life Sciences receives milestone based economics linked to the program's progress. This berobenatide funding deal with...

Yahoo · Nov 6, 2026

Pfizer (PFE) Maps Out $650 Million Connecticut Center For Global Clinical Trials

Pfizer (NYSE:PFE) plans to build a US$650 million manufacturing technology center in Connecticut to support global clinical trials. The planned facility is expected to produce clinical active pharmaceutical ingredients and drug products for Pfizer's development pipeline. Pfizer describes the project as a long term expansion of its R&D and supply chain capabilities tied to future portfolio needs. This planned US$650 million Connecticut manufacturing technology center is a key development to...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.